Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 111Unknown 80Recruiting 42Active not recruiting 22Terminated 19Not yet recruiting 14Withdrawn 4Suspended 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 20Rectal Neoplasms 11Colonic Neoplasms 9Neoplasm Metastasis 7Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Stomach Neoplasms 4Recurrence 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Motor Activity 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophagogastric Cancer 1Esophageal Squamous Cell Carcinoma 1Clinical Stage I Gastric Cancer AJCC v8 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Borderline Resectable Pancreatic Adenocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 4Paclitaxel 3Capecitabine 3pembrolizumab 2fludarabine 2Trastuzumab 2S 1 (combination) 2Ramucirumab 2Polymerase Chain Reaction 2Irinotecan 2Gastric Bypass 2Fluorouracil 2Cyclophosphamide 2Biopsy 2zimberelimab 1tusamitamab ravtansine 1talazoparib 1relatlimab 1olaparib 1milademetan 1atezolizumab 1apatinib 1XELOX 1Valganciclovir 1Taxes 1Saline Solution 1Nivolumab 1Methods 1Lubricant Eye Drops 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Stomach Neoplasms × Oxaliplatin × Clear all
NCT04863430 2025-02-21

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Peking University

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Merck Sharp & Dohme LLC

Phase 3 Withdrawn
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01070290 2014-01-07

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡